2023年5月3日

Mezzion製藥-注重一種罕見疾病的醫藥公司最近宣布,它已獲得近4000萬美元基金FUEL-2,這是它確認3期臨床試驗以及未來的商業化和其他國家的監管機構提交包括歐洲。Mezzion現在想給市場帶來JURVIGO (udenafil),這是一種高度選擇性的,獨特的,強有力的5型磷酸二酯酶抑製劑(PDE-5抑製劑)對特定使用估計全球70 k單心室先天性心髒病(SV-CHD) 12歲及以上患者經曆Fontan手術減輕。Fontan患者的平均壽命是35 - 45,除了JURVIGO之外,沒有其他當前幾種藥物進行臨床開發針對Fontan患者人群。和在Fontan JURVIGO治療的主要目的是1)提高運動能力,2)執行日常體育活動提高他們的能力以更少的努力,和3)可能改善他們的壽命和生活質量。加上另一個潛在的好處與JURVIGO治療可能會放緩Fontan Fontan-associated肝病的進展的主題。這個投資是增加實收資本從BRV資本管理(試驗項目的全球經濟增長的投資平台)。在醫療領域,BRV資本投資於生物技術公司承諾可以根據分化主導全球市場的產品。+ BRV也進行了成功的投資/退出到聖製藥和Arvelle療法。主要引用了:“我們已經獲得穩定所需的資金和積極進步FUEL-2和提交包括歐洲其他國家的監管當局。我們FUEL-2協議提交給FDA和與全球領先的作物將是有史以來最大的臨床試驗進行Fontan病人。 In addition, we are expanding on global partnerships with hospital systems, advocacy groups, provider networks, and industry leaders dedicated to improving outcomes for those with SV-CHD. Our hope is that by continuing to invest in and support the Fontan patients, others will be inspired to do the same.” — Founder and CEO Dong-Hyun Park “BRV Capital participated in the Cardiology Conference by Children’s Hospital of Philadelphia (CHOP) in Puerto Rico at the end of February of this year and met many doctors and heart disease related professionals in person as part of its diligence effort. And also, we’ve been thoroughly reviewing Mezzion’s FUEL-1 data and the U.S. FDA’s response letters and comments carefully for a long time. As a result, the possibility of new drug approval based on the FUEL-2 Protocol was evaluated very high, so the head office decided to invest in Mezzion.” “The future market value was estimated considering attainable drug price after commercialization. BRV, as an institutional investor that focuses not on short-term profits, but on differentiated technology-based investments that can substantially grow, we would like to provide support from the new drug approval of udenafil to the success of global commercialization with strong partnership. We also subscribe to Mezzion’s corporate philosophy of helping all the patients around the World who are suffering from congenital diseases to open-up a new life.” — Yoon Kwan, CIO of BRV Capital Trending on Pulse 2.0